Daiichi Suntory Pharma (Rights To 6R-BH4) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Daiichi Suntory Pharma (Rights To 6R-BH4) General Information

Description

A drug development and marketing right in Japan. The drug development right is associated to treat cardiovascular indications and genetic disease phenylketonuria (PKU).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
BioMarin Pharmaceutical
Primary Office
  • Daiichi Sankyo Building A/B 3-5-1
  • Nihonbashi-honcho
  • Tokyo, 103-8426
  • Japan
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Daiichi Suntory Pharma (Rights To 6R-BH4) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Daiichi Suntory Pharma (Rights To 6R-BH4)‘s full profile, request access.

Request a free trial

Daiichi Suntory Pharma (Rights To 6R-BH4) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Daiichi Suntory Pharma (Rights To 6R-BH4)‘s full profile, request access.

Request a free trial